Handok recently announced on the 1st that it received the Minister of Health and Welfare Award for Innovative Pharmaceutical Companies from the Ministry of Health and Welfare.
The Ministry of Health and Welfare selects innovative pharmaceutical companies that have contributed to improving public health and the development of the pharmaceutical industry through the development and distribution of excellent medicines, and awards commendations annually. Handok has maintained its qualification through re-certification after first being certified as an innovative pharmaceutical company in 2012.
Handok was recognized for providing excellent medicines and services and focusing on innovative new drug research and development. In particular, it is expanding its research areas by linking outstanding research capabilities through both in-house research and an open innovation strategy. Last year, Handok completed the Handok Future Complex in the Magok district of Gangseo-gu, Seoul, integrating the product development research institute and new drug development research institute, thereby strengthening its R&D capabilities.
Handok is developing innovative new drugs and biopharmaceuticals in the fields of cancer, diabetes, and rare diseases, as well as global-level improved new drugs and combination drugs using dual-release drug coating technology, and patch formulations using transdermal drug delivery system technology. Recently, Handok received approval from the Ministry of Food and Drug Safety for the global Phase 2 and 3 clinical trial application (IND) of the bile duct cancer treatment 'HDB001A.' This provides an opportunity to additionally secure data on Korean patients for HDB001A in the treatment area of bile duct cancer, where treatment options are limited.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
